Lumiracoxib pharmacokinetics remain unchanged between subjects with moderate degree of hepatic impairment and healthy subjects

被引：0
|
作者：
Kalbag, J
Scott, G
Yeh, CM
Gurrieri, P
Milosavljev, S
Scott, G
Rordorf, C
机构：
[1] Nova Pharmaceut Corp, Clin Pharmacol, E Hanover, NJ USA
[2] Nova Pharmaceut Corp, Clin Pharmacol, Horsham, W Sussex, England
[3] Nova Pharmaceut Corp, Clin Pharmacol, Basel, Switzerland
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 42卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
48
引用
收藏
页码：1061 / 1061
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Chevalier, Clemence
    Dubourg, Julie
    Bolze, Sebastien
    Fouqueray, Pascale
    [J]. CLINICAL PHARMACOKINETICS, 2021, 60 (04) : 485 - 490
  • [2] Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment
    Clémence Chevalier
    Julie Dubourg
    Sébastien Bolze
    Pascale Fouqueray
    [J]. Clinical Pharmacokinetics, 2021, 60 : 485 - 490
  • [3] Pharmacokinetics of Maribavir in Subjects with Moderate Hepatic Impairment
    Song, I. H.
    Ilic, K.
    Wu, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 792 - 792
  • [4] Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects
    Mangold, JB
    Gu, H
    Rodriguez, LC
    Bonner, J
    Dickson, J
    Rordorf, C
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (05) : 566 - 571
  • [5] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
  • [6] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [7] Pharmacokinetics (PK) of garenoxacin in healthy subjects and in subjects with hepatic impairment.
    Noveck, RJ
    Vargas, R
    Russo, R
    Bello, A
    Gajjar, D
    Grasela, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P79 - P79
  • [8] Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects
    Mangold, JB
    Gu, H
    Rodriguez, LC
    Scott, G
    Bonner, J
    Rordorf, C
    [J]. DRUG METABOLISM REVIEWS, 2002, 34 : 141 - 141
  • [9] A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects
    Krauwinkel, W.
    Noukens, J.
    van Dijk, J.
    Popa, S.
    Ouatas, T.
    de Vries, M.
    Phung, D.
    Gibbons, J.
    Mordenti, J.
    Mateva, L.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (03) : 268 - 275
  • [10] Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
    Frost, Charles E.
    Ly, Van
    Garonzik, Samira M.
    [J]. DRUGS IN R&D, 2021, 21 (04) : 375 - 384
12345